Psychiatry AtlasMedication guide · United States

Stimulant medicine

Methylphenidate (Ritalin, Concerta)

Generic name
methylphenidate hydrochloride
Brand names
Ritalin; Concerta
Medication class
Stimulant medicine
Forms covered
Ritalin immediate-release tablets; Concerta extended-release tablets

Article updated: 2026-10-30 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

FDA Boxed Warning

Ritalin immediate-release tablets; Concerta extended-release tablets.

Ritalin and Concerta have a high potential for abuse, misuse and addiction. Misuse can cause overdose and death. Assess and monitor risk before and during treatment, and counsel about secure storage and safe disposal.

Methylphenidate treats ADHD; immediate-release Ritalin is also approved for narcolepsy. This article covers Ritalin tablets and Concerta extended-release tablets, which have different age limits and release patterns.

What to expect: Stimulant effects can occur on the day a dose is taken, while the prescriber evaluates how well the chosen product covers your daily needs.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Attention-deficit/hyperactivity disorder (ADHD) — Adults and children aged 6 years and older. This is the Ritalin immediate-release approval; safety and effectiveness below age 6 are not established.Ritalin immediate-release tablets.
  • Attention-deficit/hyperactivity disorder (ADHD) — Patients aged 6–65 years. The selected Concerta label does not establish use above age 65 and does not recommend use below age 6.Concerta extended-release tablets.
  • Narcolepsy — Patients evaluated for narcolepsy; pediatric safety and effectiveness below age 6 are not established. Narcolepsy is listed in Ritalin labeling; it is not a Concerta indication in the selected label.Ritalin immediate-release tablets.

Read more: ADHD.

What should I expect?

Stimulant effects can occur on the day a dose is taken, while the prescriber evaluates how well the chosen product covers your daily needs. Track attention and function, or wakefulness for narcolepsy, together with appetite, sleep, mood, and pulse or blood-pressure changes.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Take the exact product as prescribed. Ritalin immediate-release tablets are usually taken before meals in divided doses; Concerta is taken each morning with or without food. Swallow Concerta whole—never split, crush, or chew it.

Concerta may be unsuitable with severe bowel narrowing or difficulty swallowing tablets whole. Its empty shell can appear in stool. Do not switch release systems or substitute equal milligram amounts yourself.

Store securely and never share. Review heart history, blood pressure, pulse, appetite, growth in children, sleep, mood, tics, and painful or discolored fingers or toes. Tell the anesthesia team before a procedure.

Allergy to methylphenidate or product ingredients. Current MAOI use or use within 14 days after stopping an MAOI.

The labels advise avoiding use in serious heart disease. Existing glaucoma or raised eye pressure needs an eye-care review and monitoring.

MAO inhibitors can cause a dangerous blood-pressure reaction. Methylphenidate may reduce the effect of blood-pressure medicines. Tell the surgical and anesthesia team about treatment because certain anesthetics interact. Changes in a regimen combining methylphenidate and risperidone may increase movement-related side effects. Review all medicines rather than assuming these examples are a complete interaction list.

The newer Concerta label describes inconsistent pregnancy findings; available evidence does not justify a blanket claim of no risk. Discuss the benefit of treatment, possible fetal risks and untreated ADHD with the care team. Methylphenidate enters breast milk in small amounts in the limited studies; monitor a breastfed infant for agitation, sleep problems, poor feeding or poor weight gain.

Ritalin ADHD approval starts at age 6. Concerta is approved for ages 6–65 and is not recommended below age 6. Growth monitoring remains important throughout pediatric treatment. The selected data do not establish a dosing approach for older adults above the studied age range.

Do not double a dose after forgetting one. A late stimulant dose may impair sleep, so ask the pharmacist for instructions for the exact preparation. Discuss planned pauses or stopping with the prescriber; after prolonged use, abrupt reduction can cause fatigue, depressed mood, appetite change or sleep disturbance. Do not create a personal switch or restart schedule from another formulation’s instructions.

What side effects should I know about?

  • Reduced appetite, weight loss, insomnia, headache, anxiety or abdominal discomfort.
  • Dry mouth, nausea, sweating, palpitations or increased pulse.
  • Concerta is not approved or recommended for children younger than 6. Younger children had higher drug exposure and more adverse effects, including weight loss, than older children at the same dose. The FDA’s June 30, 2025 warning covers extended-release stimulants. Children need height and weight monitoring; report weight loss or slowed growth to the prescriber.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Chest pain, fainting or marked shortness of breath need prompt cardiac assessment.
  • Prolonged painful erection, painful eye with visual change, severe allergic reaction or seizures require urgent help.
  • New hallucinations, mania or severe agitation need prompt clinical review; suspected overdose is an emergency.

What else should I know to stay safe?

  • Store securely and never share. Do not use after methylphenidate allergy or within 14 days after an MAOI; avoid use in serious heart disease. Monitor pulse, blood pressure, mood, tics, circulation in fingers or toes, and children’s growth. Glaucoma or raised eye pressure needs an eye-care review.
  • Concerta must not be crushed, divided, or chewed and may be unsuitable with severe bowel narrowing or inability to swallow it whole. Different release systems cannot be substituted using equal milligram amounts without prescribing advice. Planned stopping or large reductions after prolonged use also need review because withdrawal can occur.
  • Methylphenidate can interact with blood-pressure medicines, certain anesthetics, and changes in a risperidone combination. Tell the surgical team before a procedure. Discuss pregnancy and breastfeeding; exposed infants may need monitoring of sleep, feeding, and weight. Concerta’s approval is for ages 6–65; other products have their own scope.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • An empty Concerta shell can appear in stool after the medicine has been released. This is expected and does not usually mean the dose was lost.
  • Two methylphenidate products can contain the same ingredient but release it differently. A product change needs clear instructions from the prescriber or pharmacist.

How does it work?

Methylphenidate changes the handling of dopamine and norepinephrine, chemical messengers used by nerve cells. It reduces their return into cells, allowing more to remain available between them. This action is well described, although the complete explanation of how it improves attention-deficit/hyperactivity disorder (ADHD) symptoms remains uncertain.

Explore more in Brain & Science: Stimulant Transport: Methylphenidate.

How was this medicine developed?

Ritalin received U.S. approval in 1955. Concerta was approved in 2000, using an extended-release tablet to deliver methylphenidate differently through the day. The release system remains part of the prescription, not simply a change of brand name.

How do I say the name?

Methylphenidate: meth-il-FEN-ih-dayt. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Ritalin: FDA prescribing information, February 2025
  2. Concerta: FDA prescribing information, April 2026
  3. Methylphenidate: patient information
  4. Ritalin: FDA approval and product record
  5. Concerta: FDA approval and product record
  6. Concerta extended-release tablets: current prescribing information
  7. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
  8. Ritalin (methylphenidate): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..

  9. Concerta: Package Insert / Prescribing Information / MOA
  10. ISMP List of Confused Drug Names
  11. Schizophrenia
  12. NIMH: Understanding psychosis
  13. DailyMed - METADATE ER- methylphenidate hydrochloride tablet, extended release
  14. DailyMed - METADATE CD- methylphenidate hydrochloride capsule, extended release

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top